account_id none on file
legal_name Pulmonx Corp
ticker LUNG
cik 1127537
domain pulmonx.com
linkedin_company_url https://www.linkedin.com/company/pulmonx/
entry_point_account_id none on file
name Pulmonx Corporation
exchange Nasdaq
sector Health Care
hq Redwood City, CA, United States
sector index/company/sector/health-care/
calls 3 filings 0 executives 5 family 0
why_now
First, we recently executed a cost restructuring initiative that reduced our ongoing operating expenses by over 10%. With this action, we believe we have achieved an appropriate balance between expense management and continued investment in our key growth initiatives.
Mar 4, 2026 / receipt
calls
First, we recently executed a cost restructuring initiative that reduced our ongoing operating expenses by over 10%. With this action, we believe we have achieved an appropriate balance between expense management and continued investment in our key growth initiatives.
Mar 4, 2026 / receipt, needs a key / Derek Sung, COO and CFO | earnings call 2026-03-04 | transcript dd9ad16a-f9f6-4b04-8569-da0e8b75534c | chars 12349-12617 | segment 12
No, I mean, I think the only external data point I think about is, you know, level of travel has increased substantially this summer versus last summer. And as Steve mentioned, there are vacation schedules and things like that. So we're just uncertain of what the impact of seasonality will be in the quarter, specifically in the U.S. So I think we're just kind of waiting to understand that a little bit better before we kind of think about what to do with guidance.
Jul 31, 2024 / receipt, needs a key / Mehul, CFO | earnings call 2024-07-31 | transcript 2e302da8-61fd-493a-8ee0-85fec4a4b53c | chars 34577-35044 | segment 34
Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. all forward-looking statements, including, without limitation, those relating to our operating trends, commercial strategies, and future financial performance, the timing and results of clinical trials, the impact of COVID-19 on our business and prospects for recovery, expense management, expectations for hiring, growth in our organization, market opportunity, guidance for revenue, gross margin and operating expenses, commercial expansion, and product pipeline development are based upon our current estimates and various assumptions.
May 1, 2024 / receipt, needs a key / Elizabeth Sparisio, other | earnings call 2024-05-01 | transcript f51d4f4a-133d-4796-b78d-1d084398cb10 | chars 1275-1968 | segment 1
filingsnone on file
executives
| Derek Sung | Chief Operating Officer and Chief Financial Officer | - | receipt |
| Glendon E. French | President and Chief Executive Officer | - | receipt |
| Glenn French | CEO | - | receipt |
| Mehul Joshi | Chief Financial Officer | - | receipt |
| Steve Williamson | CEO | - | receipt |
familynone on file
upcoming
| 2026-11-11 | earnings call | scheduled | ir |
changes
| 2025-10-27 | President and Chief Executive Officer, appointed | sec_8k |
| 2025-10-27 | President and Chief Executive Officer, departed | sec_8k |
| 2024-04-02 | Chief Financial Officer, appointed | sec_8k |
| 2024-02-21 | President and Chief Executive Officer, appointed | sec_8k |
| 2024-02-21 | President and Chief Executive Officer, departed | sec_8k |
mcp_package_hint
slug pulmonx-corporation
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$